MEDFIELD, MA--(Marketwire - January 21, 2010) -
Highlighted Links |
http://www.symbollon.com |
"We are moving very quickly to prepare the IoGen™ product launch," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "We recently repurchased the IoGen finished goods inventory from our previous distributor. This significant inventory will advance our expected retail launch of IoGen™ by months. By partnering with Atech Solutions for the web site development and ProLog Logistics for complete state-of-the-art fulfillment and customer service needs, we believe that we will provide women looking to improve their breast health with a responsive and customer focused buying experience. Making this important female health product available to women is an important first step in helping improve the lives of millions of women concerned with their overall breast health."
Symbollon Pharmaceuticals, Inc. Resources:
-- Corporate Profile: http://symbollon.com/corporate_profile.htm -- FAQ: http://symbollon.com/faq.htm -- Technology Overview: http://symbollon.com/technology_overview.htm
About ProLog Logistics
Since its inception in 1996, ProLog Logistics has remained focused on delivering high-quality and cost-effective operational out-sourcing solutions. Utilizing two state-of-the-art distribution facilities, coupled with a centralized call center, ProLog is ideally positioned to meet the operational needs of its clients.
About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)
Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
Forward Looking Statement: This news release contains statements by the
Company that involve risks and uncertainties and may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements reflect management's current
views and are based on certain assumptions. Actual results could differ
materially from those currently anticipated as a result of a number of
factors, including, but not limited to, the risks and uncertainties
associated with whether (i) we will be able to successfully commercialize
IoGen, (ii) Symbollon will be able to obtain the resources necessary to
continue operations as a going concern, (iii) the Company will be able to
enter into new arrangements with corporate partners, (iv) management and
the Board of Directors will be able to maximize shareholder value by
leveraging the Company's proprietary technology, and (v) such other factors
as may be disclosed from time-to-time in the Company's reports as filed
with the Securities and Exchange Commission.
Contact:
Symbollon Pharmaceuticals, Inc.
Alex Johnston
Investor Relations
480-315-9982
Premier Media Service Inc.
Kelly Black
President
866-216-8814